Idea/Target | Lead | In vivo PoC | IND Enabling Studies | Phase 1 | Phase 2 | Phase 3 | Launch | |
---|---|---|---|---|---|---|---|---|
LUCID-MS |
|
IND filing anticipated in 4th Quarter 2022/First Quarter 2023 |
||||||
LUCID-PSYCH |
|
IND filing anticipated in 4th Quarter 2022/First Quarter 2023 |
||||||
FSD201 |
|
Anticipated 4th Quarter 2022. Clearance has been received by FDA and Health Canada to proceed with phase-2 clinical trials. |
Lucid-PSYCH | |
Development Stage | Preclinical |
Target Condition | Mental health and neurodegenerative conditions |
Proprietary molecules | Yes |
Time to Market | 5-8 years |
IP/Innovation | Yes |
Market Access Strategy | Multiple entry points |
Proposed mechanism of action of PEA with red lines indicating canonical signaling, black lines as strongly supported, and grey as hypothesized (the Basal Phermacology of Palmitoylethanolamide)
Receive most valuable updates straight into your inbox
SIGN UP TODAY
PLEASE SEND INVESTOR INQUIRIES TO [email protected]
ALL OTHER INQUIRIES PLEASE EMAIL [email protected]
JOIN OUR TEAM
Careers